This review is a recent study on JAK inhibitor ruxolitinib in myelofibrosis patients (JUMP) trial.
Independent expert commentary is provided by Associate Professor David Ross, a Consultant Haematologist in SA Pathology with clinical appointments at the Royal Adelaide Hospital and Flinders Medical Centre in Adelaide.
Please login below to download this issue (PDF)